A study published in 2020 evaluated AuraSTOP® in children and adolescents suffering from primary headaches, in the absence of other comorbidities.

The hiring of AuraSTOP®, conducted for three months with the use of two sachets a day, was monitored weekly through telephone contacts or e-mails with parents to verify the compliance of the subjects.

The study used several measurement tools to evaluate the effectiveness of the treatment

  • MIDAS score, which measures headache-related disability
  • HIT-6 questionnaire, which assesses the impact of headache on the patient’s life.

42 children and adolescents (25 girls and 17 males) with an average age of 10.59 ± 3.18 years were included in the study. After three months of taking, the results showed significant improvements:

  • Reduction in the number of days of headache in three months: from 17.28 ± 14.62 days in the observation phase to 4.5 ± 8.86 post-intake days.
  • Pain reduction: The mean NRS score decreased from 7.45 ± 1.74 observation period to 3.3 ± 2.26 post-take.
  • Disability reduction: the average MIDAS score went from 46.48 ± 8.35 observation period to 9.78 ± 18.16 post-intake. Improvements in the MIDAS classes: 1 subject (2.38%) worsened, 9 subjects (21.43%) showed no changes, while 32 subjects (76.19%) recorded improvements, with a significant number that improved by one (23.91%), two (28.57%) or three classes (23.91%).
  • Headache Impact Reduction: HIT-6 scores went from 62.55 ± 5.5 observation period to 46.48 ± 8.35 post-recruitment, a significant reduction.

The intake of AuraSTOP© in children and adolescents, limited to the case studies studied, showed a significant reduction in the number of days of headache, perceived pain and associated disability, significantly improving the impact of headache on the quality of life.

Limitations: The study offers interesting preliminary data, but does not provide definitive evidence of efficacy due to the absence of controlled design and small samples.

Related articles